Skip to main content
Orexo logo

Orexo — Investor Relations & Filings

Ticker · ORX ISIN · SE0000736415 LEI · 549300LJ5CCWDPTK9Z08 ST Manufacturing
Open in API
Filings indexed 843 across all filing types
Latest filing 2012-07-12 Interim / Quarterly Rep…
Country SE Sweden
Listing ST ORX

About Orexo

https://orexo.com/

Orexo is a commercial-stage pharmaceutical company focused on developing improved pharmaceuticals and digital therapies. The company addresses unmet patient needs, particularly within substance use disorders and mental health. It leverages proprietary drug delivery and formulation technologies to create innovative treatment solutions. Orexo's activities span research, development, and commercialization of its products.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2012
Interim / Quarterly Report Classification · 1% confidence The document is a comprehensive interim financial report for Orexo AB for the period ending June 2012. It contains detailed financial statements (income statement, cash flow, etc.), management commentary on business performance, clinical trial updates, and operational highlights. It is clearly a substantive financial report rather than a mere announcement or certification, fitting the definition of an Interim/Quarterly Report. H1 2012
2012-07-12 Swedish
Interim / Quarterly Report 2012
Interim / Quarterly Report Classification · 1% confidence The document is a comprehensive financial report for the six-month period ending June 30, 2012. It contains detailed financial statements, including consolidated statements of financial operations, revenue breakdowns, and management commentary on business performance and outlook. It is not an earnings release (which would be shorter and focused on highlights) nor an announcement of a report (RPA). It fits the definition of an Interim/Quarterly Report (IR) as it provides substantive financial data and analysis for a period shorter than a full fiscal year. H1 2012
2012-07-12 English
Orexo tar ett stort kliv framåt i arbetet att hjälpa personer beroende av smärtstillande opioidläkemedel
Regulatory Filings Classification · 1% confidence The document is a press release dated July 2, 2012, announcing the successful completion of a pivotal comparative bioavailability study for their product OX219 against the market leader Suboxone. It details positive clinical results, mentions upcoming discussions with the FDA regarding the approval application, and outlines the next steps (stability testing results expected Q4 2012, application planned for Q1 2013). This type of announcement, focusing on clinical trial outcomes and regulatory progress for a drug candidate, is characteristic of an Earnings Release (ER) if it were quarterly results, or more generally, a significant corporate update. Since it is not a full financial report (10-K or IR), a transcript (CT), or a management discussion (MDA), and it is a primary announcement of key operational/clinical progress, it fits best as an Earnings Release (ER) which often includes significant operational milestones alongside financial highlights, or as a general Regulatory Filing (RNS). Given the focus on clinical trial success and regulatory pathway updates, it is a major corporate event announcement. In the context of the provided definitions, 'ER' (Earnings Release) is often used for major periodic announcements of results/progress. However, since this is a specific clinical/regulatory update rather than a standard quarterly financial summary, and it doesn't fit perfectly into the other categories, 'RNS' (Regulatory Filings - general regulatory announcements/fallback) is a strong candidate. But, because it announces the successful completion of the final pivotal clinical study, which is a major milestone often highlighted in earnings reports, and it is a press release format, 'ER' is plausible if we interpret ER broadly as a major periodic announcement. Given the strong focus on clinical data and regulatory path rather than just financial figures, and the lack of a specific 'Clinical Trial Update' code, I will classify it as a general Regulatory Filing (RNS) as it is a formal announcement of a significant corporate event/data release, or potentially an 'IR' if it contained more comprehensive period financials, which it does not. Since it is a press release announcing a major development (completion of pivotal trials), and it is not a formal financial report, 'RNS' is the most appropriate fallback for a significant, non-standard filing announcement.
2012-07-02 Swedish
Orexo takes large step forward on the road to improve treatment for people dependent on opioid pain killers
Legal Proceedings Report Classification · 1% confidence The document is explicitly titled "Press release" and announces the completion of a crucial comparative bioavailability study for a product (OX219) ahead of schedule, including positive results against a competitor and plans to meet with the FDA to discuss a US marketing authorization application (NDA submission). This content focuses on a significant operational and clinical milestone, which is typical of an Earnings Release (ER) or a general announcement. Since it is a press release detailing key operational and clinical progress rather than a full financial report (10-K or IR) or a formal regulatory filing announcement (RPA/RNS), the most appropriate classification is Earnings Release (ER), as these often contain operational highlights alongside or instead of preliminary financial figures. It is not a transcript (CT), a formal audit report (AR), or a management discussion (MDA) of already released financials. Given the focus on clinical trial completion and next steps toward market entry, ER is the best fit among the provided options for a major operational update announced via press release.
2012-07-02 English
Antal aktier och röster i Orexo
Share Issue/Capital Change Classification · 1% confidence The document is a short press release (1442 characters) dated June 29, 2012, announcing a change in the total number of shares and votes in the company due to the exercise of stock options. This directly relates to a change in the capital structure or share count. The filing explicitly states that Orexo is obligated to publish this information according to financial instrument trading laws. This content aligns best with 'Share Issue/Capital Change' (SHA), as it details the resulting total share count after an issuance event (option exercise). It is not a full report (10-K, IR), an earnings release (ER), or a dividend notice (DIV). Since it is a specific announcement about the share count resulting from a capital event, SHA is the most precise fit over the general 'RNS'.
2012-06-29 Swedish
Number of shares and votes in Orexo
Share Issue/Capital Change Classification · 1% confidence The document is a short press release dated June 29, 2012, announcing a change in the total number of shares and votes in Orexo due to the exercise of warrants. This directly relates to a change in the company's capital structure or share count. Reviewing the definitions, 'Share Issue/Capital Change' (SHA) is the most appropriate category, as it covers changes in the number of shares. It is not a general regulatory filing (RNS) because it fits a specific category, nor is it a dividend notice (DIV) or director dealing (DIRS). The length is short, but the content is a direct announcement of a capital change, not an announcement *about* a report.
2012-06-29 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.